WE SEE THE FUTURE FIRST

WE SEE THE FUTURE FIRST

Minerva Biotechnologies is focused on cancer and stem cell therapeutics. We are developing cancer immunotherapies targeting 80% of solid tumors and to prevent cancer metastasis

more info
patternframe

Welcome to Minerva Biotechnologies

Exploring the Space between Cancers and Stem Cells

Cancer Therapeutics

Cancer Therapeutics

Minerva's CAR T therapeutics will attack solid tumors that are MUC1* positive. This represents approximately 80% of all cancers.

learn more
Regenerative Medicine

Regenerative Medicine

Minerva’s stem cell discoveries will enable pharmaceutical companies to utilize regenerative medicine in a variety of diseases.

learn more
AlphaSTEM™

AlphaSTEM™

Using AlphaSTEM™ iPSC generation is more efficient, cell expansion is faster, and differentiation efficiency is increased.

learn more

We See The Future First.

Minerva Biotechnologies Launches AlphaSTEM™, A Naïve Stem Cell Culture System

featured news

Minerva Biotechnologies Launches AlphaSTEM™, A Naïve Stem Cell Culture System

Minerva Biotechnologies, a leading cancer therapy and regenerative medicine company, today announced the launch of the AlphaSTEM™ Culture...

Posted on February 14, 2017

view more DETAILS

Latest News

February 14, 2017

Minerva Biotechnologies Launches AlphaSTEM™, A Naïve Stem Cell Culture System

Minerva Biotechnologies, a leading cancer therapy and regenerative medicine company,

January 4, 2017

Minerva Attending the J.P. Morgan 35th Annual Healthcare Conference 2017 in San Francisco

The Minerva team will be taking meetings at the J.P. Morgan Healthcare Conference in San

September 26, 2016

Minerva Presenting at 10yrs of iPSCs Symposium 

Dr. Cynthia Bamdad, CEO and Founder of Minerva Biotechnologies, will be presenting a

View All News

We See The Future First.

Sign Up For Our Mailing List.